The price of Myriad Genetics, Inc (NASDAQ:MYGN) shares last traded on Wall Street fell -5.62% to $4.03.
MYGN stock price is now -53.40% away from the 50-day moving average and -76.63% away from the 200-day moving average. The market capitalization of the company currently stands at $371.45M.
On May 07, 2025, Wells Fargo Downgraded its previous ‘Overweight’ rating to ‘Equal Weight’ on the stock keeping its target price maintained at $6, while ‘Guggenheim’ rates the stock as ‘Neutral’
In other news, DIAZ PAUL J, President and CEO sold 15,000 shares of the company’s stock on Oct 11 ’24. The stock was sold for $343,950 at an average price of $22.93. Upon completion of the transaction, the President and CEO now directly owns 962,378 shares in the company, valued at $3.88 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 11 ’24, Officer DIAZ PAUL J bought 15,000 shares of the business’s stock. A total of $343,950 was incurred on buying the stock at an average price of $22.93. A total of 4.37% of the company’s stock is owned by insiders.
During the past 12 months, Myriad Genetics, Inc has had a low of $4.24 and a high of $29.30. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 1.90, and a quick ratio of 1.71.
The net profit margin was -12.20% and return on equity was -13.84% for MYGN. The company reported revenue of $195.9 million for the quarter, compared to $202.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -3.12 percent.
